Page 4 - Patrick Wingrove News Today

U.S. inspectors recently uncovered new manufacturing problems at an Eli Lilly plant that has been under scrutiny by federal investigators, according to government records obtained by Reuters. ...

Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will...

Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will compete with Novo Nordisk's Wegovy and Zepbound from Eli Lilly. Amgen has an experimental dual mechanism obesity drug in mid-stage trials it hopes will have fewer side effects with less frequent dosing than Wegovy or Zepbound, Chief Scientific Officer Jay Bradner told Reuters at the annual JPMorgan health conference in San F...

Pharmaceutical executives from Amgen to Pfizer are plotting to break into the lucrative obesity market by developing or cutting deals to acquire better drugs that will compete with Novo Nordisks...

Germany's Bayer will continue its expansion into the U.S. despite its November announcement that its promising blood thinner candidate failed to demonstrate superiority over a competing medicine, the drugmaker's pharmaceuticals head Stefan Oelrich said on Monday. Bayer's experimental anticoagulant asundexian could still be a blockbuster if its second trial for stroke prevention reads out positively, Oelrich told Reuters at the JPMorgan health conference in San Francisco. He said...

Eli Lilly CEO David Ricks on Monday said the company's powerful weight-loss drug Zepbound hit 25,000 new prescriptions per week at the end of December and that its 2024...

Eli Lilly CEO David Ricks on Monday said the company's powerful weight-loss drug Zepbound hit 25,000 new prescriptions per week at the end of December, and that its 2024 supply may not be enough to meet demand. "I think it's important to set expectations, but we're working hard to fulfill demand," he told Reuters at the annual JPMorgan health conference in San Francisco. Ricks declined to provide details on how much Zepbound Lilly can produce now, or to forecast 2024 d...

CVS Health said on Wednesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April 1, and will recommend biosimilar versions of the medicine instead. CVS said Hyrimoz and an unbranded version of Humira, both from Swiss drugmaker Sandoz, will be covered across all its formularies, while branded and unbranded near copies of the drug from India's Biocon will be covered on some reimbursement lists. ...

Drugmakers including Pfizer, Sanofi and Takeda Pharmaceutical plan to raise prices on more than 500 drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors.

Drugmakers including Pfizer, Sanofi and Takeda Pharmaceutical plan to raise prices in the United States on more than 500 drugs in early January, according to data analyzed...